tirzepatide deaths Weight-loss drug may lower heart failure Tirzepatide reduces CV death, worsening

The authors would like to thank all the participants

Following an FDA nod for oral Wegovy in December 2025, alternatives now cater to individuals preferring tablets over injections

At 4mg, the phase 2 trial showed 17.1% average weight loss at 48 weeks, which exceeds the maximum dose of semaglutide (14.9%) in its own trial

Brand Trust Flywheel Critical in crowded market 7

Scheduling was quick, the patient portal was simple to use, and uploading documents and completing forms only took a few minutes.The medical staff at ProlongMD were friendly, professional, and highly knowledgeable

At 0.5 to 2 mg, the dose is low enough that many people report feeling almost nothing for the first few days